YAP1 and breast carcinoma: Based on its previously reported role as a determinant of drug response in breast cancer patients, along with its contribution to an improved determination of breast cancer subtypes, SPAG5 might hold the potential to be a promising biomarker, which identifies patients who could benefit from drugs targeting YAP/TAZ activities, either alone or in combination with other treatments.